{
    "nct_id": "NCT03702231",
    "official_title": "Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients That Are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n* Diagnosis of CLL/SLL which is made according to the updated criteria of the NCI Working Group\n* Cohort 1:Treatment naive CLL/SLL patients\n* Cohort 2: Subjects must be receiving treatment ibrutinib for at least 6 months prior to administration of the first vaccine dose\n* Cohort 3: Subjects must be receiving acalabrutinib for at least 6 months prior to administration of the first vaccine dose\n* No active, symptomatic VZV or herpes zoster infection within 12 months prior to vaccination\n* No exposure to the live VZV vaccine (ZOSTAVAX) within 12 months prior to vaccination\n* No prior exposure to the SHINGRIX vaccine\n* Age greater than or equal to 18 years.\n* ECOG performance status of 0-2\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n\nEXCLUSION CRITERIA:\n\n* Female patients who are currently in pregnancy\n* Any uncontrolled active systemic infection\n* Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk\n* Severe allergic reaction to any component of SHINGRIX.\n* Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination.\n* Concomitant use of immunosuppressive agents (e.g. steroids, radio\n\ntherapy, chemotherapy)\n\n* Hereditary or acquired immunodeficiency syndrome unrelated to chronic lymphocytic leukemia\n* Non-English speaking individuals will be excluded from the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}